Benefit of Inactivated Influenza Vaccine in Infants in Iran: A Community based Randomized Control Trial


1 Medical Ethics Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Mashhad, Iran. Tel: +985138002388; Email:

2 Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 PhD, Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 MD-MpH, School of Health, Management & Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


Background: Influenza in infants and young children is a major medical problem which causes excess medical visits, antibiotic prescriptions and hospitalization even in otherwise healthy children. Many of the developed countries have recommended influenza vaccination for all children (>6month old), but the economic benefit of this strategy is not clear especially for developing countries. Objectives: To find the difference in the incidence of influenza-like illness (ILI) and economic cost related to it between TIV vaccinated and non-vaccinated infants in Mashhad, Iran. Methods: This was a community randomized controlled trial which was started in November 2005 and ended up at May 2006. Each of the study and control groups were composed of 500 infants between 6 month and 20 months old who were brought for routine vaccination. The study group was given two doses of TIV; the control group received routine care without any extra intervention. Both groups were followed by monthly telephone calls (up to six months after the vaccination) and were asked about signs and symptoms of flu like illnesses and any cost related to them. SPSS 11.5 was used for statistical analysis, P


1.Principi N, Esposito S. Are we ready for universal influenza vaccination in pediatrics? Lancet Infect Dis. 2004;4(2):75-83.
doi: 10.1016/S1473-3099(04)00926-0. [PubMed: 14871631].
2. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane
Database Syst Rev. 2018;2:CD004879. doi: 10.1002/14651858. CD004879.pub5. [PubMed: 29388195].
3. Usonis, V, Anca I, André F, Chlibek R, Ivaskeviciene I, Mangarov A, et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children. BMC Infect Dis. 2010;10:168. doi:
10.1186/1471-2334-10-168. [PubMed: 20546586].
4. Statement, Australian Technical Advisory Group on Immunisation (ATAGI). Clinical advice for immunisation
providers regarding the administration of 2012 trivalent seasonal influenza vaccines. Australia: Department of Health
and Ageing Australian Government; 2012.
5. Halloran ME, Piedra PA, Longini IM Jr, Gaglani MJ, Schmotzer B, Fewlass C, et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant,
during 2003-2004. Vaccine. 2007;25(20):4038-45. doi: 10.1016/j.vaccine.2007.02.060. [PubMed: 17395338].
6. Heikkinen T, Heinonen S. Effectiveness and safety of influenza vaccination in children: European perspective. Vaccine. 2011; 29(43):7529-34. doi: 10.1016/j.vaccine.2011.08.011. [PubMed:21820481].
7. Patrick O, Ron D, Jachen M, Jose Antonio N, Pekka N, Caraten P, et al. Technical report of the scientific panel on vaccines and immunization infant and children seasonal immunization against influenza on a routine basis during inter-pandemic period. Available at: URL: files/media/en/publications/Publications/0701_TER_Scientifi c_Panel_on_Vaccines_and_Immunisation.pdf; 2007.
8. Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine. 2006;24(5):629-35. doi: 10.1016/j.vaccine.2005.08.054. [PubMed: 16157429].
9. Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, et al. Effectiveness of inactivated influenza
vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003;290(12):1608-16.
doi: 10.1001/jama.290.12.1608. [PubMed: 14506120].
10. Cochran LW, Black S, Klein NP, Dekker CL, Lewis E, Reingold AL. Vaccine effectiveness against laboratory-confirmed
influenza in infants: a matched case control study. Hum Vaccine. Hum Vaccine. 2010;6:9. doi: 10.4161/hv.6.9.12470.
[PubMed: 20855940].
11. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis. 2011;11(1):23-9. doi: 10.1016/S1473- 3099(10)70255-3. [PubMed: 21106443].
12. Katayose M, Hosoya M, Haneda T, Yamaguchi H, Kawasaki Y, Sato M, et al. The effectiveness of trivalent inactivated
influenza vaccine in children over six consecutive influenza seasons. Vaccine. 2011;29(9):1844-9. doi: 10.1016/j.vaccine.
2010.12.049. [PubMed: 21195802].
13. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8years of age, with 1 vs 2 doses. Pediatrics. 2005;116(1):153-9. doi: 10.1542/peds.2005-0049. [PubMed: 15995046].
14. Allison MA, Daley MF, Crane LA, Barrow J, Beaty BL, Allred N, et al. Influenza vaccine effectiveness in healthy 6- to 21-monthold children during the 2003-2004 season. J Pediatr. 2006; 149(6):755-62. doi: 10.1016/j.jpeds.2006.06.036. [PubMed:17137887].
15. Lee VJ, Tok MY, Chow VT, Phua KH, Ooi EE, Tambyah PA, et al. Economic analysis of pandemic influenza vaccination
strategies in Singapore. PLoS One. 2009;4(9):e7108. doi: 10.1371/journal.pone.0007108. [PubMed: 19771173].
16. Porras-Ramírez A, Alvis-Guzmán N, Rico-Mendoza A, AlvisEstrada L, Castañeda-Orjuela CA, Velandia-González MP, et al. Cost effectiveness of influenza vaccination in children under 2 years old and elderly in Colombia. Rev Salud Publica (Bogota). 2009;11(5):689-99. [PubMed: 20339595].
17. Dayan GH, Nguyen VH, Debbag R, Gómez R, Wood SC. Costeffectiveness of influenza vaccination in high-risk children in Argentina. Vaccine. 2001;19(30):4204-13. doi: 10.1016/ S0264-410X(01)00160-8. [PubMed: 11457546].
18. Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ. Costeffectiveness study on influenza prevention in Hong Kong.
Health Policy. 2001;56(3):215-34. doi: 10.1016/S0168-8510
(00)00140-8. [PubMed: 11399347].